Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer
- 465 Downloads
Recently, mutations in the epidermal growth factor receptor (EGFR) gene were reported to correlate with EGFR tyrosine kinase inhibitor response in advanced non-small cell lung cancer (NSCLC). In this study, we attempted to detect EGFR mutations in plasma and pleural effusion samples and to make clear its correlations with gefitinib response and survival in NSCLC patients.
The free DNA was isolated from the plasma of 56 cases and pleural effusion of another 32 cases of advanced NSCLC. Five common types of EGFR mutations were analyzed by LightCycle PCR with Taqman-MGB probes.
EGFR gene mutations were found in 22 of all the 88 (25%) NSCLC patients (23.2% of 56 plasma samples, 28.1% of another 32 pleural effusion samples). EGFR mutations were more frequently present in females, never-smokers and adenocarcinomas (P < 0.01). It also showed that patients with EGFR mutations had a significantly better response rate when compared with that of the wild-type patients (P < 0.001). The median progression-free survival (11.2 vs. 2.7 months P = 0.005) and overall survival (21.8 vs. 5.8 months P = 0.003) were significantly higher in patients with EGFR mutations than in patients with wild-type EGFR.
The EGFR mutations in the serum and the pleural effusion from advanced NSCLC patients can be detected with LightCycle PCR using Taqman-MGB probes. The mutations highly predict the efficacy of gefitinib in advanced NSCLC.
KeywordsNon-small cell lung cancer Plasma Pleural effusion Epidermal growth factor receptor mutation PCR
This work was supported by a grant from Science and Technology Commission of Shanghai Municipality (No. 06DZ19502)
- Bosari S, Marchetti A, Buttitta F, Graziani D, Borsani G, Loda M et al (1995) Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis. A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 4:249–255. doi: 10.1097/00019606-199512000-00004 CrossRefPubMedGoogle Scholar
- Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B et al (2006b) Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 12:3915–3921. doi: 10.1158/1078-0432.CCR-05-2324 CrossRefPubMedGoogle Scholar
- Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158. doi: 10.1001/jama.290.16.2149 CrossRefPubMedGoogle Scholar
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139. doi: 10.1056/NEJMoa040938 CrossRefPubMedGoogle Scholar
- Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865. doi: 10.1200/JCO.2005.08.043 CrossRefPubMedGoogle Scholar
- Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520. doi: 10.1200/JCO.2005.00.992 CrossRefPubMedGoogle Scholar
- Moran T, Paz-Ares L, Isla D et al. (2007) High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients with poor performance status. In: ASCO annual meeting proceedings Part I, vol 25, No.18S, pp 7505Google Scholar
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(13):306–311Google Scholar
- Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al. (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl):2379–2385Google Scholar
- Sonobe M, Tanaka F, Wada H (2004) Lung cancer—related genes in the blood. Ann Thorac Cardiovasc Surg 10:2l3–2l217Google Scholar
- Therasse P, Arbuck SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216. doi: 10.1093/jnci/92.3.205 CrossRefPubMedGoogle Scholar
- Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ (2007) Detection of epidermal growth factor receptor mutations in non-small-cell lung cancer by rea1-time PCR using TaqMan-MGB probes. Chin J Oncol 29:119–123Google Scholar